Exelixis, Inc. (0IJO.L)
USD 33.32
(-9.14%)
USD 33.32
(-9.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 678.44 Million USD | 16.36% |
| 2022 | 583.06 Million USD | 43.74% |
| 2021 | 405.62 Million USD | 57.08% |
| 2020 | 258.22 Million USD | 29.3% |
| 2019 | 199.7 Million USD | 48.11% |
| 2018 | 134.83 Million USD | -63.59% |
| 2017 | 370.33 Million USD | -27.13% |
| 2016 | 508.22 Million USD | 16.39% |
| 2015 | 436.64 Million USD | -1.39% |
| 2014 | 442.78 Million USD | 1.31% |
| 2013 | 437.04 Million USD | 2.92% |
| 2012 | 424.66 Million USD | 40.32% |
| 2011 | 302.63 Million USD | -48.63% |
| 2010 | 589.11 Million USD | 16.17% |
| 2009 | 507.13 Million USD | 10.76% |
| 2008 | 457.88 Million USD | 40.19% |
| 2007 | 326.6 Million USD | 7.15% |
| 2006 | 304.8 Million USD | 10.67% |
| 2005 | 275.41 Million USD | 14.44% |
| 2004 | 240.66 Million USD | 22.6% |
| 2003 | 196.31 Million USD | 20.29% |
| 2002 | 163.19 Million USD | 49.18% |
| 2001 | 109.39 Million USD | 165.93% |
| 2000 | 41.13 Million USD | 89.57% |
| 1999 | 21.7 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 653.38 Million USD | -3.31% |
| 2024 Q3 | 684.85 Million USD | 4.82% |
| 2024 Q1 | 675.74 Million USD | -0.4% |
| 2023 Q3 | 629.29 Million USD | 2.4% |
| 2023 FY | 678.44 Million USD | 16.36% |
| 2023 Q1 | 588.22 Million USD | 0.89% |
| 2023 Q2 | 614.53 Million USD | 4.47% |
| 2023 Q4 | 678.44 Million USD | 7.81% |
| 2022 Q3 | 469.97 Million USD | -4.12% |
| 2022 Q2 | 490.14 Million USD | 36.05% |
| 2022 FY | 583.06 Million USD | 43.74% |
| 2022 Q1 | 360.26 Million USD | -11.18% |
| 2022 Q4 | 583.06 Million USD | 24.06% |
| 2021 Q2 | 324.19 Million USD | 16.05% |
| 2021 Q1 | 279.35 Million USD | 8.18% |
| 2021 FY | 405.62 Million USD | 57.08% |
| 2021 Q4 | 405.62 Million USD | 20.98% |
| 2021 Q3 | 335.29 Million USD | 3.42% |
| 2020 Q4 | 258.22 Million USD | -0.31% |
| 2020 Q1 | 207.95 Million USD | 4.13% |
| 2020 Q2 | 213.22 Million USD | 2.54% |
| 2020 Q3 | 259.01 Million USD | 21.47% |
| 2020 FY | 258.22 Million USD | 29.3% |
| 2019 Q1 | 156.77 Million USD | 16.27% |
| 2019 FY | 199.7 Million USD | 48.11% |
| 2019 Q4 | 199.7 Million USD | 10.24% |
| 2019 Q3 | 181.14 Million USD | 17.27% |
| 2019 Q2 | 154.46 Million USD | -1.47% |
| 2018 Q4 | 134.83 Million USD | 24.38% |
| 2018 Q1 | 105.14 Million USD | -71.61% |
| 2018 Q3 | 108.4 Million USD | -20.41% |
| 2018 FY | 134.83 Million USD | -63.59% |
| 2018 Q2 | 136.19 Million USD | 29.52% |
| 2017 Q3 | 371.05 Million USD | 0.82% |
| 2017 Q4 | 370.33 Million USD | -0.2% |
| 2017 Q2 | 368.02 Million USD | -21.23% |
| 2017 Q1 | 467.23 Million USD | -8.07% |
| 2017 FY | 370.33 Million USD | -27.13% |
| 2016 Q2 | 663.27 Million USD | 2.28% |
| 2016 Q4 | 508.22 Million USD | -1.6% |
| 2016 Q1 | 648.48 Million USD | 48.52% |
| 2016 Q3 | 516.46 Million USD | -22.13% |
| 2016 FY | 508.22 Million USD | 16.39% |
| 2015 Q1 | 429.69 Million USD | -2.96% |
| 2015 FY | 436.64 Million USD | -1.39% |
| 2015 Q4 | 436.64 Million USD | -0.19% |
| 2015 Q3 | 437.46 Million USD | 0.12% |
| 2015 Q2 | 436.96 Million USD | 1.69% |
| 2014 Q1 | 426.08 Million USD | -2.51% |
| 2014 Q3 | 442.16 Million USD | 1.09% |
| 2014 Q2 | 437.39 Million USD | 2.65% |
| 2014 FY | 442.78 Million USD | 1.31% |
| 2014 Q4 | 442.78 Million USD | 0.14% |
| 2013 Q1 | 404.67 Million USD | -4.71% |
| 2013 Q4 | 437.04 Million USD | 3.27% |
| 2013 Q3 | 423.19 Million USD | 1.79% |
| 2013 Q2 | 415.75 Million USD | 2.74% |
| 2013 FY | 437.04 Million USD | 2.92% |
| 2012 Q2 | 275.43 Million USD | -1.72% |
| 2012 Q3 | 421.76 Million USD | 53.13% |
| 2012 FY | 424.66 Million USD | 40.32% |
| 2012 Q4 | 424.66 Million USD | 0.69% |
| 2012 Q1 | 280.25 Million USD | -7.39% |
| 2011 FY | 302.63 Million USD | -48.63% |
| 2011 Q3 | 408.58 Million USD | -23.77% |
| 2011 Q4 | 302.63 Million USD | -25.93% |
| 2011 Q2 | 535.99 Million USD | -5.05% |
| 2011 Q1 | 564.48 Million USD | -4.18% |
| 2010 Q3 | 590.49 Million USD | -6.92% |
| 2010 Q1 | 483.5 Million USD | -4.66% |
| 2010 Q2 | 634.41 Million USD | 31.21% |
| 2010 Q4 | 589.11 Million USD | -0.23% |
| 2010 FY | 589.11 Million USD | 16.17% |
| 2009 Q1 | 444.05 Million USD | -3.02% |
| 2009 Q2 | 456.79 Million USD | 2.87% |
| 2009 Q3 | 563.87 Million USD | 23.44% |
| 2009 Q4 | 507.13 Million USD | -10.06% |
| 2009 FY | 507.13 Million USD | 10.76% |
| 2008 Q1 | 321.17 Million USD | -1.66% |
| 2008 FY | 457.88 Million USD | 40.19% |
| 2008 Q4 | 457.88 Million USD | 64.58% |
| 2008 Q3 | 278.21 Million USD | -8.65% |
| 2008 Q2 | 304.56 Million USD | -5.17% |
| 2007 Q1 | 351.16 Million USD | 15.21% |
| 2007 Q4 | 326.6 Million USD | 2.17% |
| 2007 Q3 | 319.65 Million USD | -2.54% |
| 2007 FY | 326.6 Million USD | 7.15% |
| 2007 Q2 | 327.98 Million USD | -6.6% |
| 2006 Q4 | 304.8 Million USD | 24.25% |
| 2006 Q1 | 303.06 Million USD | 10.04% |
| 2006 Q3 | 245.32 Million USD | -3.8% |
| 2006 Q2 | 255.01 Million USD | -15.85% |
| 2006 FY | 304.8 Million USD | 10.67% |
| 2005 Q4 | 275.41 Million USD | 8.36% |
| 2005 Q1 | 236.64 Million USD | -1.67% |
| 2005 FY | 275.41 Million USD | 14.44% |
| 2005 Q3 | 254.15 Million USD | -3.34% |
| 2005 Q2 | 262.93 Million USD | 11.11% |
| 2004 FY | 240.66 Million USD | 22.6% |
| 2004 Q1 | 187.01 Million USD | -4.74% |
| 2004 Q2 | 180.07 Million USD | -3.71% |
| 2004 Q3 | 187.2 Million USD | 3.96% |
| 2004 Q4 | 240.66 Million USD | 28.56% |
| 2003 Q3 | 153.37 Million USD | -3.4% |
| 2003 FY | 196.31 Million USD | 20.29% |
| 2003 Q2 | 158.76 Million USD | -3.95% |
| 2003 Q1 | 165.29 Million USD | 1.29% |
| 2003 Q4 | 196.31 Million USD | 28.0% |
| 2002 Q2 | 89.44 Million USD | -2.26% |
| 2002 FY | 163.19 Million USD | 49.18% |
| 2002 Q1 | 91.51 Million USD | -16.35% |
| 2002 Q3 | 91.15 Million USD | 1.92% |
| 2002 Q4 | 163.19 Million USD | 79.03% |
| 2001 Q1 | 43.77 Million USD | 6.42% |
| 2001 Q3 | 97.3 Million USD | 14.49% |
| 2001 Q4 | 109.39 Million USD | 12.42% |
| 2001 FY | 109.39 Million USD | 165.93% |
| 2001 Q2 | 84.99 Million USD | 94.15% |
| 2000 Q3 | 29.14 Million USD | -13.67% |
| 2000 Q4 | 41.13 Million USD | 41.17% |
| 2000 FY | 41.13 Million USD | 89.57% |
| 2000 Q1 | 35.72 Million USD | 0.0% |
| 2000 Q2 | 33.75 Million USD | -5.5% |
| 1999 FY | 21.7 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -8.722% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -438.026% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -9.833% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -156.273% |
| bluebird bio, Inc. | 424.62 Million USD | -59.775% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -886.7% |
| Imunon, Inc. | 8.53 Million USD | -7853.236% |
| Editas Medicine, Inc. | 150.05 Million USD | -352.128% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 96.702% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 80.646% |
| Myriad Genetics, Inc. | 312.9 Million USD | -116.825% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 33.447% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -39.179% |
| Verastem, Inc. | 71.18 Million USD | -853.073% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.015% |
| Waters Corporation | 3.47 Billion USD | 80.485% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.692% |
| Biogen Inc. | 12.04 Billion USD | 94.368% |
| Nektar Therapeutics | 267.04 Million USD | -154.055% |
| Perrigo Company plc | 6.04 Billion USD | 88.77% |
| Dynavax Technologies Corporation | 375.02 Million USD | -80.907% |
| Illumina, Inc. | 4.36 Billion USD | 84.461% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1828.654% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -246.609% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -164.523% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1719.278% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 64.104% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -723.026% |
| Evolus, Inc. | 209.68 Million USD | -223.551% |
| Adicet Bio, Inc. | 37.12 Million USD | -1727.707% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1586.583% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 90.454% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -2.672% |
| FibroGen, Inc. | 585.72 Million USD | -15.829% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 86.205% |
| OPKO Health, Inc. | 622.47 Million USD | -8.991% |
| Homology Medicines, Inc. | 118.53 Million USD | -472.368% |
| Geron Corporation | 146.12 Million USD | -364.284% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 83.25% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -3280.225% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -5312.837% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -170.504% |
| Zoetis Inc. | 9.29 Billion USD | 92.701% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -70.782% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1279.626% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 86.826% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1300.444% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 73.94% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 71.793% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -490.918% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 58.869% |
| Blueprint Medicines Corporation | 918.64 Million USD | 26.147% |
| Insmed Incorporated | 1.66 Billion USD | 59.173% |
| TG Therapeutics, Inc. | 169.08 Million USD | -301.245% |
| Incyte Corporation | 1.59 Billion USD | 57.391% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 42.776% |